The EPS miss and accelerating cash burn without a clear funding path for Phase 2b are negative signals. Monitor the May 18 CRC review for Cohort 1 safety data — a positive read could provide a near-term catalyst, but the fundamental cash constraint limits upside until a financing event occurs.
Price Chart
Executive Summary
Skye Bioscience reported Q1 2026 EPS of -$0.32, missing consensus of -$0.29 by 10.3%, with a net loss of $12.5M vs $11.1M a year ago. The company highlighted clinical progress in its CBeyond expansion study for nimacimab but faces a cash runway only through Q4 2026, excluding Phase 2b costs, creating significant funding uncertainty.
Key Financial Metrics
Key Facts
- Q1 2026 EPS -$0.32 vs consensus -$0.29 (10.3% miss)
- Net loss widened to $12.5M from $11.1M YoY
- Cash, equivalents and short-term investments: $17.1M as of March 31, 2026
- Cash runway only through Q4 2026, excluding Phase 2b costs
- R&D expenses rose to $7.9M from $7.2M YoY
- CBeyond Expansion Study Cohort 1 enrollment initiated; CRC review May 18, 2026
- Topline data from CBeyond Expansion Study expected Q4 2026
- Weighted average shares outstanding: 39.7M (basic and diluted)
Financial Impact
EPS miss of $0.03 per share; net loss increased by $1.4M YoY; cash burn rate ~$4.3M/month
Risk Factors
- Cash runway only through Q4 2026, requiring dilutive financing or partnership to fund Phase 2b
- EPS miss of 10.3% vs consensus signals operational underperformance
- Net loss widening YoY with no near-term revenue prospects
- Clinical trial risk: nimacimab may fail to meet safety/efficacy endpoints in expansion study
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293281 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 20, 2026 6w ago | DEFA14A | $0.2809 $1.77 | ▲ +528.34% | ▲ +528.34% | $1.68 (+498.08%) |
Aug 14, 2026 7w ago | 8-K | $0.5015 $1.99 | ▲ +296.81% | ▲ +298.80% | $1.68 (+235.00%) |
Aug 14, 2026 7w ago | Press Release | $0.5015 $1.99 | ▼ −296.81% | ▼ −298.80% | $1.68 (−235.00%) |
May 15, 2026 20w ago | 8-K | $0.7780 $0.7184 | ▲ +7.66% | ▲ +9.24% | $1.68 (−115.94%) |
May 12, 2026 20w ago | Press Release | $0.8140 $0.7800 | ▲ +4.18% | ▲ +2.45% | $1.68 (−106.39%) |
Apr 29, 2026 22w ago | 3 | $0.8940 $0.8500 | ▼ −4.92% | ▼ −10.97% | $1.68 (+87.92%) |
Apr 16, 2026 24w ago | DEFA14A | $0.7500 $0.8200 | ▲ +9.33% | ▲ +3.52% | $1.68 (+124.00%) |
Apr 2, 2026 26w ago | Press Release | $0.6980 $0.8790 | ▲ +25.93% | ▲ +16.05% | $1.68 (+140.69%) |
Mar 10, 2026 29w ago | Press Release | $0.7210 $0.7260 | ▲ +0.69% | ▲ +0.17% | $1.68 (+133.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access